Beauty
Health
Lifestyle
Medicine
Biowatch
Column
Kormedi.com TV
Notice
Newsletter subscription
Beauty
Health
Lifestyle
Medicine
Biowatch
Column
Kormedi.com TV
Notice
Languages
ENGLISH
English (US)
ASIAN
Монгол
日本語
Tiếng Việt
Bahasa Indonesia
中文 (简体, 中国大陆)
EUROPEAN
Русский
Español (España)
Français (France)
MIDDLE_EAST_AFRICA
العربية
Search results for "GLP-1 drugs"
Home
Do Wegovy and Mounjaro Count as Doping? WADA Monitors GLP-1 Drugs in Sports
GLP-1 (glucagon-like peptide-1) class medications, such as Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro, are increasingly recognized for benefits...
09/01/2026, 21:54 ET
Considering Wegovy for Weight Loss? South Korea's Drug Safety Ministry Warns It Is Not for Everyone
South Korea’s Ministry of Food and Drug Safety issued a strong warning on July 8 against the misuse and abuse of GLP-1 class anti-obesity...
07/12/2026, 06:56 ET
The GLP-1 Paradox: Wegovy and Mounjaro Patients Shed Weight, but Walk Less
"First I’ll lose the weight, and then I’ll start exercising." It is a thought shared by almost anyone starting highly...
06/19/2026, 16:27 ET
GLP-1 Weight-Loss Drugs: Potential Metabolic Instability Linked to Long-Term Use
A new study suggests that the long-term administration of GLP-1 receptor agonists—the class of anti-obesity medications...
05/03/2026, 07:56 ET
GLP-1 Drugs and Bone Health: Studies Highlight Fracture Risks in Elderly Patients
The GLP-1 receptor agonist class of drugs, widely used for the treatment of obesity and type 2 diabetes, has...
03/13/2026, 06:16 ET
The Unexpected Heart Benefits of Weight Loss Injections: Reducing Complications After Heart Attack
New research indicates that the class of drugs used in popular weight loss injections may do more than shed pounds;...
03/09/2026, 08:11 ET
The Surprising Life-Saving Potential of Weight Loss Meds in Diabetic Foot Care
GLP-1 receptor agonists (such as Wegovy and Ozempic), currently dominating the headlines as weight loss medications,...
02/06/2026, 02:40 ET
Hanmi Pharmaceutical Nears Korean Launch for Obesity Drug EPPE After Five-Year Detour
Licensed out to French pharmaceutical giant Sanofi in 2015 and returned five years later, Hanmi Pharmaceutical’s...
09/03/2026, 05:34 ET
Hanmi Licenses Muscle-Preserving Obesity Drug Candidate to Genentech in $2.3 Billion Deal
Hanmi Pharmaceutical has entered into an exclusive global licensing agreement with Genentech, a member of the Roche...
08/27/2026, 23:49 ET
Samsung Biologics Bets 2.7 Trillion Won on Peptides in South Korea’s Largest Biotech M&A Deal
Samsung Biologics is making a major push into peptide-based medicines—widely used in weight-loss and diabetes...
07/22/2026, 03:25 ET
1
2
3
Next